Terminal cancer patient criticises plans to ban NHS patients from receiving life-extending drug

Credit: BPM

A woman diagnosed with terminal breast cancer has criticised plans to ban NHS patients from receiving a life-extending drug - because of the cost.

35-year-old newlywed Katrina Keyte, was diagnosed with secondary breast cancer in June 2015 after learning the disease had returned and spread to her liver and lungs.

She had been advised to start taking Kadcyla after her current treatment - which could extend her life by months or even years.

But the National Institute for Health and Care Excellence, the health regulator, has now said it may not be recommending the drug for routine use on the NHS.

The controversial draft decision is said to be after negotiations with drug-maker Roche Products broke down - with full treatment currently put at around £90,000 per patient.

Katrina, from Smethwick, fears she and others could lose out on precious extra months with their loved ones.

She said:

Katrina Keyte Credit: BPM

HMV store supervisor Katrina underwent a lumpectomy and chemotherapy, as well as radiotherapy at the Queen Elizabeth Hospital. But two years later she was told the cancer had returned after she developed a cough.

An X-ray and CT scan revealed that she had a tumour in her lung and liver, and that her cancer was now incurable.

Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:

Katrina is backing a petition launched by charity Breast Cancer Now to urge NICE and drug maker Roche Products to find a solution to overturn the draft decision.

The petition will be handed in on Tuesday January 24 and so far more than 90,000 people have already signed up.